Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.41 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20111117 | 1.00 | EGFR (0.41) | EGFRMAP3K7IRAK4USP2SMN1; SMN2 | |
| SCHEMBL18791703 | 1.00 | EGFR (0.41) | EGFRMAP3K7IRAK4USP2SMN1; SMN2 | |
| SCHEMBL18791988 | 0.91 | EGFR (0.40) | EGFRMAP3K7IRAK4USP2SMN1; SMN2 | |
| SCHEMBL20110985 | 0.91 | EGFR (0.40) | EGFRMAP3K7IRAK4USP2SMN1; SMN2 | |
| SCHEMBL18791991 | 0.91 | EGFR (0.40) | EGFRMAP3K7IRAK4USP2SMN1; SMN2 | |
| SCHEMBL20110991 | 0.89 | EGFR (0.38) | EGFRMAP3K7IRAK4USP2SMN1; SMN2 | |
| SCHEMBL18791655 | 0.89 | EGFR (0.38) | EGFRMAP3K7IRAK4USP2SMN1; SMN2 | |
| SCHEMBL18791657 | 0.89 | EGFR (0.38) | EGFRMAP3K7IRAK4USP2SMN1; SMN2 | |
| SCHEMBL18791699 | 0.89 | EGFR (0.38) | EGFRMAP3K7IRAK4TRPV4ALK | |
| SCHEMBL20111388 | 0.89 | EGFR (0.38) | EGFRMAP3K7IRAK4TRPV4ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | EGFR 4338/4885MAP3K7 306/4885IRAK4 2954/4885 |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | EGFR 4329/4885MAP3K7 166/4885IRAK4 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.